Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer

Weekly administration of nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) has been shown to be a safe and effective treatment for metastatic breast cancer (MBC) in clinical studies. We conducted a multicenter, randomized, open‐label phase II study to compare the efficacy and safety of weekly n...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Kenji, Inoue, Kenichi, Masuda, Norikazu, Takao, Shintaro, Kashiwaba, Masahiro, Tokuda, Yutaka, Iwata, Hiroji, Yamamoto, Naohito, Aogi, Kenjiro, Saeki, Toshiaki, Nakayama, Takahiro, Sato, Nobuaki, Toyama, Tatsuya, Ishida, Takanori, Arioka, Hitoshi, Saito, Mitsue, Ohno, Shinji, Yamauchi, Hideko, Yamada, Kimito, Watanabe, Junichiro, Ishiguro, Hiroshi, Fujiwara, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448660/
https://www.ncbi.nlm.nih.gov/pubmed/28256066
http://dx.doi.org/10.1111/cas.13221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448660/
https://www.ncbi.nlm.nih.gov/pubmed/28256066
http://dx.doi.org/10.1111/cas.13221

Ejemplares similares